Péter Ábrányi-Balogh

Email: abranyi-balogh.peterttkhu
Phone: +36 1 3826 961

Scientific interests: chemical probes, covalent labelling of proteins, antibody-conjugates, new multicomponent reactions, beta-carboline and isoquinoline alkaloids, reaction mechanisms, organophosphorous compounds

CV ORCID MTMT

Selected publications

1. Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease
   Douangamath, A.; Fearon, D.; Gehrtz, P.; Krojer, T.; Lukacik, P.; Owen, C. D.; Resnick, E.; Strain-Damerell, C.; Aimon, A.; Ábrányi-Balogh, P.; Brandaõ-Neto, J.; Carbery, A.; Davison, G.; Dias, A.; Downes, T. D.; Dunnett, L.; Fairhead, M.; Firth, J. D.; Jones, S. P.; Keeley, A.; Keserű, G. M.; Klein, H. F.; Martin, M. P.; Noble, M. E. M.; O’Brien, P.; Powell, A.; Reddi, R.; Skyner, R.; Snee, M.; Waring, M. J.; Wild, C.; London, N.; von Delft, F.; Walsh, M. A.
   bioRxiv, 2020, 2020.05.27.118117, accepted to Nature Communications



2. Covalent fragment libraries in drug discovery
   Aaron Keeley, László Petri, Péter Ábrányi-Balogh, György M.Keserű
   Drug Discovery Today, 2020, 25 (6), 983-996.



3. A road map for prioritizing warheads for cysteine targeting covalent inhibitors
   Péter Ábrányi-Balogh, László Petri, Tímea Imre, Péter Szijj, Andrea Scarpino, Martina Hrast, Ana Mitrović, Urša Pečar Fonovič, Krisztina Németh, Hélène Barreteau, David I. Roper, Kata Horváti, György G.Ferenczy, Janko Kos, Janez Ilaš, Stanislav Gobec, György M.Keserű
   European Journal of Medicinal Chemistry, 2018, 160, 94-107.



4. Design and characterization of a heterocyclic electrophilic fragment library for the discovery of cysteine-targeted covalent inhibitors
   Aaron Keeley, Peter Abranyi-Balogh and George M Keserű
   MedChemComm, 2019, 10, 263-267.



5. Synthesis and fluorescent properties of boroisoquinolines, a new family of fluorophores
   Dénes Sóvári, Attila Kormos, Orsolya Demeter, András Dancsó, György Miklós Keserű, Mátyás Milen and Péter Ábrányi-Balogh
   RSC Advances, 2018, 8, 38598-38605.